United-Guardian: United-Guardian Reports Y/Y Rise in Q3 Earnings, Flat Revenues

In This Article: United-Guardian, Inc. UG reported strong results for third-quarter 2024, demonstrating its resilience through growth in key product segments and effective cost management. With stable revenues across its portfolio, UG has effectively navigated challenges in its pharmaceutical operations while capitalizing on rising demand within the cosmetics market. The company's commitment to innovation and operational efficiency has bolstered profitability, positioning United-Guardian for sustained growth as it anticipates a rebound in its pharmaceutical segment. Q3 Results United-Guardian reported a modest 35.7% increase in its third-quarter 2024 earnings per share of 19 cents from 14 cents in the prior-year quarter. The company's total quarterly sales were $3.06 million, unchanged from the year-ago quarter. Quarterly earnings can be attributed primarily to effective cost management and increased demand for its cosmetic ingredients segment. United-Guardian, Inc. Price, Consensus and EPS Surprise United-Guardian, Inc. Price, Consensus and EPS Surprise United-Guardian, Inc. price-consensus-eps-surprise-chart | United-Guardian, Inc. Quote Disaggregated Sales by Products Cosmetic Ingredients : This segment posted 8% year-over-year sales growth. The rise was driven by increased orders from United-Guardian's largest cosmetic distributor, highlighting a sustained product demand. Medical Lubricants : Sales in this category dipped 2% year over year, attributed to standard fluctuations in order patterns, reflecting the segment's variability. Pharmaceutical Products : The pharmaceutical segment's sales dropped 6% from third-quarter 2023. This was partly due to the ongoing effects of a supply disruption at a contract manufacturer that impacted the production of Renacidin - a flagship pharmaceutical product. Despite this, the company is optimistic about a recovery in this segment as supply stabilizes. Profitability Metrics United-Guardian's operating income rose 31.5% to $0.95 million in the third quarter of 2024 from $0.72 million in the year-ago quarter. Total other income improved from $65,325 in third-quarter 2023 to $147,157 in the reported quarter, driven by a gain on marketable securities and higher investment income. After accounting for taxes, net income reached $0.9 million, marking a 38% increase from $0.6 million in the prior-year quarter. This improvement was achieved despite flat sales. Cost Analysis Total costs and expenses for the third quarter of 2024 declined to $2.1 million from $2.3 million in the prior-year period. Key contributors to this reduction were the cost of sales, which decreased significantly to $1.4 million from $1.7 million. Operating expenses increased to $0.6 million from $0.5 million, indicating higher spending on operational needs. Research and development expenses also saw an uptick, reaching $0.1 million from $98,141. This investment signals a commitment to innovation, particularly in segments like cosmetics and pharmaceuticals, wherein product development could enhance sales. Management View Management suggested optimism about sales growth as production issues surrounding Renacidin are resolved. This resolution could positively impact revenues from pharmaceutical products in subsequent quarters. Conclusion United-Guardian's third-quarter 2024 results reflect stable revenues, substantial earnings growth and improved cost management. With rising cosmetic ingredient sales and anticipated recovery in pharmaceuticals, the company appears positioned for steady performance, although it remains sensitive to operational and order pattern fluctuations across segments. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United-Guardian, Inc. (UG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research